Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
高成長
同社の収益は過去3年間にわたり着実に増加しており、年平均で91.78%の成長率を示しています。
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 7.70Mに達しています。
高い利益成長
同社の純利益は業界をリードしており、最新の年間純利益はUSD 7.70Mです。
適正水準
同社の最新のPEは-8.22で、過去3年間の水準と比較して適正圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は115.89M株で、前四半期比で2.66%減少しています。
ETHSXが保有
スター投資家ETHSXは本銘柄を89.70K株保有しています。